• Xeris Biopharma Holdings, Inc. reported past second-quarter 2026 results with revenue rising to US$92.1 million from US$71.54 million a year earlier, while net loss widened to US$31.1 million from US$1.93 million and basic loss per share from continuing operations increased to US$0.18 from US$0.01.
• Despite higher losses, the company also reported first-half 2026 revenue of US$175.23 million versus US$131.66 million and tightened its full-year 2026 total revenue guidance to US$385 million–US$390 million, offering investors clearer expectations for near-term top-line performance.
• With Xeris tightening its 2026 revenue guidance range, we will now examine how this update influences the company’s broader investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Xeris Biopharma Holdings Investment Narrative Recap

To own Xeris Biopharma, you need to believe its focused endocrine and diabetes portfolio can translate strong revenue growth into sustainable profitability, despite ongoing net losses. The latest results show solid top line momentum but much weaker earnings, so the tightened 2026 revenue guidance looks more like a refinement than a major shift in the near term catalyst of scaling Recorlev, Gvoke, and Keveyis. The biggest risk remains rising costs outpacing revenue, which this quarter’s wider loss has highlighted rather than resolved.

Among recent announcements, the appointment of CEO John Shannon as Board Chair and the addition of Dr. Nerissa Kreher to the Board stand out. This governance change lands just as Xeris reports widening losses and tightens revenue guidance, which may matter for how capital is allocated between commercial expansion and pipeline programs like XP-8121. For investors watching execution risk around expenses and portfolio concentration, who is setting priorities at the top is now more visible.

Yet behind the revenue guidance and leadership updates, there is a less obvious risk that investors should be aware of around rising R&D and SG&A costs and...

Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028. This requires 21.5% yearly revenue growth and a $116.8 million earnings increase from -$32.0 million today.

Uncover how Xeris Biopharma Holdings' forecasts yield a $11.14 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting revenue to reach about US$602 million and earnings of roughly US$164 million, so compared with the latest widened losses, that is a far more upbeat story that assumes cost pressure and portfolio concentration risks will ease rather than intensify over time, and it is a reminder that your view on Xeris can differ widely from others and may shift as this new data is digested.

Explore 3 other fair value estimates on Xeris Biopharma Holdings - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Xeris Biopharma Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.